Technical Analysis for PRLD - Prelude Therapeutics Incorporated
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 3.77 | -1.05% | -0.04 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -1.05% | |
| 50 DMA Resistance | Bearish | -1.05% | |
| 200 DMA Support | Bullish | -1.05% | |
| Pocket Pivot | Bullish Swing Setup | -1.05% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 6 hours ago |
| 20 DMA Resistance | about 7 hours ago |
| Down 3% | about 9 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Down 2 % | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/01/2024
Prelude Therapeutics Incorporated Description
Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Lymphoma Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Small Molecule Therapies Glioblastoma Multiforme Phosphoinositide 3 Kinase Inhibitor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.83 |
| 52 Week Low | 1.66 |
| Average Volume | 45,694 |
| 200-Day Moving Average | 3.63 |
| 50-Day Moving Average | 3.86 |
| 20-Day Moving Average | 3.82 |
| 10-Day Moving Average | 3.80 |
| Average True Range | 0.28 |
| RSI (14) | 47.09 |
| ADX | 8.98 |
| +DI | 17.15 |
| -DI | 15.85 |
| Chandelier Exit (Long, 3 ATRs) | 3.59 |
| Chandelier Exit (Short, 3 ATRs) | 4.22 |
| Upper Bollinger Bands | 4.06 |
| Lower Bollinger Band | 3.58 |
| Percent B (%b) | 0.4 |
| BandWidth | 12.50 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.04 |
| MACD Histogram | -0.0029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.14 | ||||
| Resistance 3 (R3) | 4.13 | 4.00 | 4.08 | ||
| Resistance 2 (R2) | 4.00 | 3.91 | 4.00 | 4.06 | |
| Resistance 1 (R1) | 3.89 | 3.85 | 3.94 | 3.89 | 4.04 |
| Pivot Point | 3.76 | 3.76 | 3.78 | 3.76 | 3.76 |
| Support 1 (S1) | 3.64 | 3.66 | 3.70 | 3.65 | 3.50 |
| Support 2 (S2) | 3.51 | 3.60 | 3.51 | 3.48 | |
| Support 3 (S3) | 3.40 | 3.51 | 3.46 | ||
| Support 4 (S4) | 3.40 |
